Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG

BACKGROUND: The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy. CASE PRESENTATION: We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyp...

Descripción completa

Detalles Bibliográficos
Autores principales: Linder, Katherine, Gandhiraj, Deepthi, Hanmantgad, Madhura, Seiter, Karen, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962515/
https://www.ncbi.nlm.nih.gov/pubmed/27468365
http://dx.doi.org/10.1186/s40164-016-0051-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962515/
https://www.ncbi.nlm.nih.gov/pubmed/27468365
http://dx.doi.org/10.1186/s40164-016-0051-4

Ejemplares similares